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Abstract Four new [D-MetO2]dermorphin tetrapeptides with substituted N- and C-terminal groups and a thymine-modified alanine residue at 
position 4were prepared and tested for their activity. All analogues were found to be ¢t-opioid receptor ligands. Two of them, H-Tyr-D-MetO-Phe- 
TalNHR (R=H, Ad) displayed an extremely high ¢t-opioid receptor selectivity comparable with that of the most/l-selective agonists among opioid 
peptides. 
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1. Introduction 
A number of opioid peptide analogues showing a selectivity 
for p-opioid receptors were obtained by substitution of various 
natural or artificial amino acids, amino acid deletions and end- 
group modifications [1,2]. The N-terminal tetrapeptideamide of 
dermorphin (DM/1--4/) is almost as p-selective as the parent 
natural heptapeptide which exhibits a rather high p selectivity 
[3]. The tetrapeptide analogues derived from DM/I-4/ and 
bearing the N-terminal guanidino-group and an adamantyl- 
amide moiety at the C-terminal appear to show a high prefer- 
ence for p receptors over ~ ones [4]. Substitution of D-methion- 
ine-sulfoxide (D-MetO) for D-AIa 2 results in compounds that 
are more p-selective than the parent etrapeptide [5]. Introduc- 
tion of aromatic and bulky proteinogenic or other amino acid 
residues, such as phenylalanine, tryptophan or naphtylalanine 
ones, into position 4 produces an affinity increase both at the 
p and ~ receptors and a high preference for p receptors [6]. In 
previous papers we have shown that insertion of a 3-(thyminyl- 
l)alanine residue (TaD into position 4 of the enkephalin and 
short dermorphin structures gives rise to analogues with a high 
p-opioid selectivity [7,8]. 
In the search for potent p-selective ligands we synthesized 
and tested for opioid activities for dermorphin tetrapeptide 
[o-MetO2]analogues bearing Tal at position 4 and N- or C- 
terminal modifications. 
2. Materials and methods 
2.t. Chemical synthesis 
DL-Tal was prepared by the three-step chemical procedure as de- 
scribed in [9], and its L-isomer was obtained enzymatically [l 0]. Boc-Pal 
was synthesized as described previously [11]. Adamantyl- and D-phen- 
ylethylamides of Tat were prepared by a method similar to that de- 
scribed by Salvadori et al. [12]. The [D-Met2]dermorphin analogues were 
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Abbreviations: Ad, 1-adamantyl; DAGO, H-Tyr-D-Ala-Gly-MePhe- 
Gly-ol; DM/I~/, dermorphin tetrapeptide, H-Tyr-D-AIa-Phe-GIy- 
NH2; DSLET, H-Tyr-D-Ser-Gly-Phe-Leu-Thr-OH; GPI, guinea-pig 
ileum; MVD, mouse vas deferens; Tal, 3-(thyminyl-1)alanine. 
prepared in solution via 3 + t coupling, using active esters. Boc-pep- 
tide-sulfides were oxidized with hydrogen peroxide in acetic acid to 
yield sulfoxides as in [5,13]. Guanidino derivatives were obtained by 
treating the respective peptideamides with l-amidino-3,5-dimeth- 
ylpyrazole nitrate as in [14]. The homogeneity ofthe final peptides and 
intermediates was demonstrated byTLC, HPLC, electrophoresis and 
amino acid analysis (Sumbatyan, N.V. and Korshunova, G.A., unpub- 
lished). 
2.2. Binding assay 
The selectivity of the compounds synthesized was characterized by 
the relative opioid receptor affinity (IC50~/IC5~u), asdetermined by 
displacement of selective radioligands from the rat brain membrane 
preparation [15,16]. [3H]DAGO and [3H]DSLET were used as selective 
/1- and d~-receptor radioligands. 
2.3. Biological activity on isolated organs 
Isolated guinea pig ileum (GPI) and mouse vas deferens (MVD) were 
prepared and used as described by Ward et al. [17]. 
3. Results and discussion 
The structures of the newly synthesized compounds can be 
described by the general formula, X-Tyr-D-MetO-Phe-Tal- 
NHR, where X stands for H or amidino-group (HN=C(NH~) -  
and R represents 1-adamanthyl of D-l-phenylethyl moieties. 
The opioid activities of the novel dermorphin analogues syn- 
thesized (I-IV) determined by in vitro assays of GPI and MVD 
and by the binding assays are reported in Table 1 and along 
with the corresponding activities of the parent tetrapeptide 
DM/1-4/, DAGO and DSLET. 
In the [3H]DAGO and [3H]DSLET binding assays, all new 
[TaP]tetrapeptides I-IV, like DM/14/ ,  displayed a greater pref- 
erence for p-subtypes over ~-receptors. Compared to the parent 
DM/1--4/peptide, analogues I, II and IV were more potent in 
the [3H]DAGO binding assays. Analogue III showed a some- 
what lower affinity for p-receptors than DM/ I~/ .  All com- 
pounds, except for analogue II, whose activity was almost equal 
to that of DM/1-4/, were far less potent in the [3H]DSLET 
binding assays than DM/I-4L The introduction of bulky hy- 
drophobic residues into the C-terminal abide moiety affected 
the binding affinity in a different manner. Compared to parent 
peptide I, adamantly derivative II was more potent both in the 
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Table 1 
The inhibitory effect of dermorphin analogues on the electrically induced contractions ofGPI and MVD and the binding of [3H]DAGO (1 nM) and 
[3H]DSLET (1 nM) in crude rat brain homogenates in IC50 a 
Compound GPI MVD [3H]DAGO (,u) [3H]DSLET (6) IC5o (6) 
IC50 (nM) ICso (nM) IC50 (nM) IC5o (nM) IC50 (g) 
H-Tyr-o-MetO-Phe-Tal-NH 2 (I) 31 + 13 > 10,000 5.0 + 2.3 7000 + 2300 1400 
H-Tyr-D-MetO-Phe-TaI-NH-Ad (II) 57.5 + 23 > 10,000 0.5 + 0.13 476 + 67 952 
H-Tyr-D-MetO-Phe-TaI-NH-D-CH(Ph)Me (1II) 575 + 35 > 10,000 45 + 35.5 7544 _+ 181 168 
NH=C(NH2)-Tyr-D-MetO-Phe-Tal-NH 2 (IV) 68 + 6 950 _+ 106 4.55 + 1.0 1177 + 300 259 
DM(1--4) 58 + 14 860 _+ 80 40 + 9 890 + 100 22 
DAGO 2.7 + 0.5 140 + 31 1.0 + 0.2 110 + 16 110 
DSLET 66 +11 0.12+0.1 95 +10 7.0+0.7 0.7 
aThe IC50 values are the mean + S.E.M. for 3-5 observations. 
[3H]DAGO and [3H]DSLET binding assays. This confirms the 
previous data obtained for short dermorphin analogues [I 8]. By 
comparison with structurally related peptide I, D-phenylethyl- 
amide derivative III exhibited the same affinity for d-receptors 
and lower affinity for B-receptors. The substitution of a guani- 
dino group for the NH2-terminal group in the parent peptide 
I left the B-affinity unaltered and decreased the d-affinity. The 
replacement of Gly by Tal 4 in the corresponding structurally 
related peptides kept constant (I, III, IV) or increased (II) the 
affinity for the B-site and lowered (I, III, IV) or maintained (II) 
the affinity for the d-site [5,13,19]. 
As revealed by the binding assays and by the tests on isolated 
organs (GPI and MVD), all [D-MetO2,Tala]dermorphin 
tetrapeptides (I-IV) displayed a very high preference for B- 
receptors over d-receptors due to their high affinity for B-sites 
and poor affinity for d-sites. Although it was not possible to 
derive accurate estimates of the selectivity from GPI/MVD 
data, one can conclude that peptides I and II are the most 
potent and, probably, most selective B-ligands among the syn- 
thesized analogues. Similar conclusions can be drawn from the 
binding assays: the IC50d/IC5~ values for compounds I and II 
are equal to 1400 and 952, respectively. 
Peptides I- IV are 5 to 35 times more selective in comparison 
to the corresponding [D-MetO2,Gly4]dermorphin tetrapep- 
tideamides described previously [5]. The synthesized com- 
pounds (I-IV) appear to have a comparable or significantly 
increased selectivity in comparison with the most selective ana- 
logues among the series of [o-MetO2]dermorphin tetrapeptides, 
including Gly, Sar and D-Ala at position 4 [5]. Thus, analogues 
I and II exhibit an extraordinary selectivity comparable to 
that of morphiceptin, LY164929 (NMe-Tyr-D-AIa-Gly-NEt- 
CH(CH2Phe)CHzNMe2), and PL017 (H-Tyr-Pro-MePhe-D- 
Pro-NH2) and rank below only syndyphalin, DALDA (H-Lys- 
Tyr-D-Arg-Phe-Lys-NH2), and Lys-DALDA, the most 
selective peptide B-ligands reported to data [1]. 
The effect of Tal addition on the opioid receptor selectivity 
of dermorphin tetrapeptides may be rationalized in terms of 
ligand conformational properties. A conformational restriction 
on ligand structure is known to be an absolute requirement for 
its interaction with B-receptor sites [1,20]. Earlier it has been 
found that the presence of MetO 2 in the D configuration i the 
dermorphin tetrapeptide structures i critical for the formation 
of 'active' conformers [21]. In the case of [D-MetO2]analogues 
modified with thymine the biological active conformation may 
be additionally stabilized ue to the presence of the nucleic acid 
base, which is known to participate in different hydrogen 
bonds, with peptide groups in particular [22]. Our early CD 
data have indicated a decrease in the conformational flexibility 
of nucleoamino acids in solution due to intramolecular hydro- 
gen bonding [23]. Besides, the conformation-function analysis 
of dermorphin and its pentapeptide analogues indicated that 
the peptide backbone structure of the [Tal4]DM/1-5/analogue 
is stabilized by hydrogen bonds [24]. 
In conclusion, the results presented indicate that the substitu- 
tion of Tal for Gly at position 4 of [o-MetO2]dermorphin 
tetrapeptide series gives rise to analogues with a further in- 
creased B-selectivity. 
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